-
Je něco špatně v tomto záznamu ?
High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience
T. Kabut, B. Weinbergerová, F. Folber, M. Lengerová, J. Mayer
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Freely Accessible Science Journals
od 1997 do Před 1 rokem
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- acyklovir terapeutické užití MeSH
- antivirové látky terapeutické užití MeSH
- cytomegalovirové infekce * etiologie prevence a kontrola farmakoterapie MeSH
- Cytomegalovirus MeSH
- lidé MeSH
- prospektivní studie MeSH
- retrospektivní studie MeSH
- transplantace hematopoetických kmenových buněk * škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
There is only limited data on cytomegalovirus (CMV) prophylaxis with high-dose (HD) aciclovir after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We performed a retrospective analysis on a total of 179 patients who underwent their allo-HSCT with HD-aciclovir prophylaxis at our center. A clinically significant CMV infection (cs-CMVi) was observed in 56 (31%) cases with a median time of 49 (range 25-147) days after HSCT. A significantly higher CMV infection rate was observed in seropositive recipients with a seronegative donor (74%) compared to seropositive recipients with a seropositive donor, and seronegative recipients with seropositive and seronegative donors (24%, 18%, 7% respectively; p < 0.001). The CMV serostatus was the only significant risk factor for CMV infection in our analysis. CMV disease developed in three patients with CMV-related death in two cases. During HD-aciclovir prophylaxis, we did not observe any medical condition attributable to HD-aciclovir's adverse effects. Compared to published results, we observed a low incidence of cs-CMVi with HD-aciclovir prophylaxis in several patient subgroups, especially in seropositive recipients with a seropositive donor. With respect to the determined threshold, HD-aciclovir prophylaxis seems to have good efficacy in an intermediate cs-CMVi risk patients, but prospective randomized trials would be needed for definite conclusions.
Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000880
- 003
- CZ-PrNML
- 005
- 20240213093435.0
- 007
- ta
- 008
- 240109s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-023-02081-6 $2 doi
- 035 __
- $a (PubMed)37612466
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kabut, Tomáš $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000325353219
- 245 10
- $a High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience / $c T. Kabut, B. Weinbergerová, F. Folber, M. Lengerová, J. Mayer
- 520 9_
- $a There is only limited data on cytomegalovirus (CMV) prophylaxis with high-dose (HD) aciclovir after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We performed a retrospective analysis on a total of 179 patients who underwent their allo-HSCT with HD-aciclovir prophylaxis at our center. A clinically significant CMV infection (cs-CMVi) was observed in 56 (31%) cases with a median time of 49 (range 25-147) days after HSCT. A significantly higher CMV infection rate was observed in seropositive recipients with a seronegative donor (74%) compared to seropositive recipients with a seropositive donor, and seronegative recipients with seropositive and seronegative donors (24%, 18%, 7% respectively; p < 0.001). The CMV serostatus was the only significant risk factor for CMV infection in our analysis. CMV disease developed in three patients with CMV-related death in two cases. During HD-aciclovir prophylaxis, we did not observe any medical condition attributable to HD-aciclovir's adverse effects. Compared to published results, we observed a low incidence of cs-CMVi with HD-aciclovir prophylaxis in several patient subgroups, especially in seropositive recipients with a seropositive donor. With respect to the determined threshold, HD-aciclovir prophylaxis seems to have good efficacy in an intermediate cs-CMVi risk patients, but prospective randomized trials would be needed for definite conclusions.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Cytomegalovirus $7 D003587
- 650 _2
- $a acyklovir $x terapeutické užití $7 D000212
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a cytomegalovirové infekce $x etiologie $x prevence a kontrola $x farmakoterapie $7 D003586
- 650 12
- $a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
- 650 _2
- $a antivirové látky $x terapeutické užití $7 D000998
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Weinbergerová, Barbora $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Weinbergerova.Barbora@fnbrno.cz $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Weinbergerova.Barbora@fnbrno.cz $1 https://orcid.org/0000000164602471
- 700 1_
- $a Folber, František $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000017034769X
- 700 1_
- $a Lengerová, Martina $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Mayer, Jiří $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 58, č. 11 (2023), s. 1229-1236
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37612466 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093432 $b ABA008
- 999 __
- $a ok $b bmc $g 2049474 $s 1210574
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 58 $c 11 $d 1229-1236 $e 20230823 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20240109
